The review follows past findings from recent studies of seroprevalence in heavily affected countries and regions (e. g. Wuhan, China and Spain), which have shown that despite intense resource stress and unprecedented over-mortality, seroprevalence rates at the population point remain low. of the seroprevalence of the U. S. population. have been limited to regional hot spots, such as New York.
“This patient population is not only ethnically and socioeconomically representative, but is one of the few teams of other people who can be tested repeatedly. Because kidney disease is an eligible condition for Medicare, they don’t face much access. restrict testing among the general population,” said Shuchi Anand, MD, director of Stanford University’s Center for Tubulointerstitial Kidney Disease and lead author of the study. “We were able to discover, with a point of maximum precision, the differences in seroprevalence between patient teams within and between regions of the United States, offering a very rich picture of the first wave of the COVID-19 epidemic that can help identify methods to curb the epidemic by targeting vulnerable populations. “
The study demonstrates the urgent need for public conditioning efforts to continue for COVID-19, paying more attention to some of the communities at peak risk known to researchers: black-majority and Hispanic neighborhoods, low-income neighborhoods, and densely populated metropolitan areas.
The effects showed that, compared to the predominantly white non-Hispanic population, other people living in predominantly black and Hispanic neighborhoods were between two and four times more likely to be inflamed with COVID-19 (COVID-19 infection rates were 11. 3% to 16. 3%). % in black and Hispanic neighborhoods, compared to 4. 8% in the predominantly white non-Hispanic population) Array while the poorest spaces were probably twice as high, and densely populated spaces were 10 times more likely to be HIV positive for SARS-CoV-2.
In the study, researchers tested the seroprevalence of ANTI-SARS-CoV-2 antibodies in a randomly decided representative pattern of 28503 patients to provide a national estimate of SARS-CoV-2 exposure in the first wave of the pandemic. 89% were assessed in the first two weeks of July. The pattern was representative of American dialysis patients divided by age, sex, race, ethnicity, and region, except that those pattern patients were less likely to be non-Hispanic black than the general adult American population. The patron’s patients lived in 46 states and 1013 U. S. counties. But it’s not the first time
Taking into account the sensitivity of the externally validated test, seroprevalence ranged from 8. 2% to 9. 4% in the sample population. The researchers estimated that the standardized seroprevalence of SARS-CoV-2 in the US population was not a problem. But it’s not the first time It was about 9. 3%. significant regional variation of less than 5% in the western United States to more than 25% in the Northeast.
Comparing knowledge of seroprevalence with the number of instances consistent with 100,000 residents of Johns Hopkins University, the authors estimate that 9. 2% of HIV patients have been diagnosed.
The authors point to several limitations, adding the fact that the hemodialysis procedure at the center can also come with the use of public or private shared shipping to and from the establishment, thus expanding the perspective of exposure. Conversely, because dialysis patients are less likely to be hired and most likely to have reduced mobility, knowledge would possibly underestimate overall seroprevalence in the general population. Finally, dialysis patients would likely be dead or hospitalized due to SARS-CoV-2 infection headaches. In the case, these patients would not have been provided with the test at dialysis centers, creating a survival bias and providing decreased exposure estimates.
Despite these limitations, this review shows that a surveillance strategy based on monthly testing of the remaining plasma of dialysis patients can produce useful estimates of the spread of SARS-CoV-2, aggregating disadvantaged and hard-to-reach populations in the United States. United. Such monitoring can indicate disease trends, resource allocation, and the effectiveness of network responses to the COVID-19 pandemic.
“This study obviously confirms that despite maximum COVID-19 levels in the United States, the number of other people with antibodies remains low and we have not yet achieved collective immunity. Until an effective vaccine is approved, we want to make sure that our most vulnerable populations are affected by the curtains of preventive measures,” dr. Julie Parsonnet, professor of medicine at Stanford University.